

### **KOS Diagnostic Lab**

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

NAME : Mr. VINOD WADHWA

AGE/ GENDER : 65 YRS/MALE PATIENT ID : 1693073

COLLECTED BY : REG. NO./LAB NO. : 042412080002

 REFERRED BY
 : 08/Dec/2024 08:56 AM

 BARCODE NO.
 : A1260073
 COLLECTION DATE
 : 08/Dec/2024 11:07AM

 CLIENT CODE.
 : KOS DIAGNOSTIC SHAHBAD
 REPORTING DATE
 : 08/Dec/2024 04:08PM

CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

# HAEMATOLOGY GLYCOSYLATED HAEMOGLOBIN (HBA1C)

GLYCOSYLATED HAEMOGLOBIN (HbA1c):

5.8

%

4.0 - 6.4

WHOLE BLOOD

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

ESTIMATED AVERAGE PLASMA GLUCOSE by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

119.76

mg/dL

60.00 - 140.00

**INTERPRETATION:** 

AS PER AMERICAN DIABETES ASSOCIATION (ADA):		
REFERENCE GROUP	GLYCOSYLATED HEMOGL	OGIB (HBAIC) in %
Non diabetic Adults >= 18 years	<5.7	
At Risk (Prediabetes)	5.7 – 6.	4
Diagnosing Diabetes	>= 6.5	
	Age > 19 Y	ears
	Goals of Therapy:	< 7.0
Therapeutic goals for glycemic control	Actions Suggested:	>8.0
	Age < 19 Y	ears
	Goal of therapy:	<7.5

#### COMMENTS:

- 1. Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.
- 2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.
- 3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

  4. High

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia,increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)





CLIENT CODE.

### **KOS Diagnostic Lab**

(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

: 08/Dec/2024 04:08PM

NAME : Mr. VINOD WADHWA

**AGE/ GENDER** : 65 YRS/MALE **PATIENT ID** : 1693073

COLLECTED BY : REG. NO./LAB NO. : 042412080002

 REFERRED BY
 : 08/Dec/2024 08:56 AM

 BARCODE NO.
 : A1260073
 COLLECTION DATE
 : 08/Dec/2024 11:07AM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

: KOS DIAGNOSTIC SHAHBAD


Test Name Value Unit Biological Reference interval

REPORTING DATE

#### LIFOTRONIC Graph Report

Name :	Case:	Patient Type :	Test Date: 08/12/2024 15:46:21
Age:	Department:	Sample Type: Whole Blood EDTA	Sample ld: A1260073
Gender:			Total Area: 11966

Peak Name	Retention Time(s)	Absorbance	Area	Result (Area %)
HbA0	67	4070	10710	85.8
HbA1c	38	62	562	5.8
La1c	24	40	326	2.6
HbF	19	16	60	0.5
Hba1b	13	46	198	1.6
Hba1a	11	31	110	0.9





DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana
KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana
0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



## **KOS Diagnostic Lab**

(A Unit of KOS Healthcare)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME : Mr. VINOD WADHWA

**AGE/ GENDER** : 65 YRS/MALE **PATIENT ID** : 1693073

COLLECTED BY : REG. NO./LAB NO. : 042412080002

 REFERRED BY
 : 08/Dec/2024 08:56 AM

 BARCODE NO.
 : A1260072
 COLLECTION DATE
 : 08/Dec/2024 11:07 AM

 CLIENT CODE.
 : KOS DIAGNOSTIC SHAHBAD
 REPORTING DATE
 : 08/Dec/2024 12:11 PM

**CLIENT ADDRESS**: 6349/1, NICHOLSON ROAD, AMBALA CANTT

Test Name Value Unit Biological Reference interval

# CLINICAL CHEMISTRY/BIOCHEMISTRY CREATININE

CREATININE: SERUM 1.43<sup>H</sup> mg/dL 0.40 - 1.40 by ENZYMATIC, SPECTROPHOTOMETRY



DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)





## **KOS Diagnostic Lab**

(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mr. VINOD WADHWA

**AGE/ GENDER** : 65 YRS/MALE **PATIENT ID** : 1693073

**COLLECTED BY** REG. NO./LAB NO. : 042412080002

REFERRED BY **REGISTRATION DATE** : 08/Dec/2024 08:56 AM BARCODE NO. : A1260074 **COLLECTION DATE** : 08/Dec/2024 11:02AM CLIENT CODE. : KOS DIAGNOSTIC SHAHBAD REPORTING DATE :08/Dec/2024 12:52PM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Value** Unit **Biological Reference interval Test Name** 

#### CLINICAL PATHOLOGY

#### MICROALBUMIN/CREATININE RATIO - RANDOM URINE

MICROALBUMIN: RANDOM URINE by SPECTROPHOTOMETRY	79.63 <sup>H</sup>	mg/L	0 - 25
CREATININE: RANDOM URINE by SPECTROPHOTOMETRY	49.58	mg/dL	20 - 320
MICROALBUMIN/CREATININE RATIO - RANDOM URINE	160.61 <sup>H</sup>	mg/g	0 - 30

by SPECTROPHOTOMETRY

INTERPRETATION:-

MATERIA REPARTOR.		
PHYSIOLOGICALLY NORMAL:	mg/L	0 - 30
MICROALBUMINURIA:	mg/L	30 - 300
GROSS PROTEINURIA:	mg/L	> 300

- Long standing un-treated Diabetes and Hypertension can lead to renal dysfunction.

  2. Diabetic nephropathy or kidney disease is the most common cause of end stage renal disease(ERSD) or kidney failure.

  3. Presence of Microalbuminuria is an early indicator of onset of compromised renal function in these patients.

  4. Microalbuminuria is the condition when urinary albumin excretion is between 30-300 mg & above this it is called as macroalbuminuria, the presence of which indicates serious kidney disease, but of cardiovascular disease in patients with dibotes & bypertension.
- 5.Microalbuminuria is not only associated with kidney disease but of cardiovascular disease in patients with dibetes & hypertension.

6.Microalbuminuria reflects vascular damage & appear to be a marker of of early arterial disease & endothelial dysfunction.

NOTE:- IF A PATIENT HAS = 1+ PROTEINURIA (30 mg/dl OR 300 mg/L) BY URINE DIPSTICK (URINEANALYSIS), OVERT PROTEINURIA IS PRESENT AND TESTING FOR MICROALBUMIN IS INAPPROPIATE. IN SUCH A CASE, URINE PROTEIN:CREATININE RATIO OR 24 HOURS TOTAL URINE MICROPROTEIN IS APPROPIATE.

\*\*\* End Of Report \*\*\*



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

